Target Name: DCUN1D1
NCBI ID: G54165
Review Report on DCUN1D1 Target / Biomarker Content of Review Report on DCUN1D1 Target / Biomarker
DCUN1D1
Other Name(s): DCN1, defective in cullin neddylation 1, domain containing 1 | defective in cullin neddylation protein 1-like protein 1 | DCUN1D1 variant 1 | defective in cullin neddylation 1 domain containing 1 | RP42 | squamous cell carcinoma-related oncogene | DCNL1 | Squamous cell carcinoma-related oncogene | RP42 homolog | DCNL1_HUMAN | DCN1-like protein 1 | Defective in cullin neddylation protein 1-like protein 1 | Tes3 | DCUN1 domain-containing protein 1 | SCCRO | SCRO | DCUN1L1 | Defective in cullin neddylation 1 domain containing 1, transcript variant 1 | DCN1-like protein 1 (isoform 1)

DCUN1D1: A Promising Drug Target / Biomarker

DCUN1D1 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the uncoupling protein (UCP) family, which plays a crucial role in the regulation of intracellular energy metabolism. UCP genes have been implicated in a wide range of physiological processes, including stress response, DNA damage repair, and cell survival. DCUN1D1 has also been shown to be involved in a number of cellular processes that are important for brain development and function, including the regulation of neurotransmitter release and the establishment of the blood-brain barrier.

The search for potential drug targets and biomarkers is an important aspect of modern medicine. The identification of a protein that is involved in a particular disease or process can lead to the development of new treatments that can effectively diagnose and treat the disease. In the case of DCUN1D1, it is possible that this protein could be a drug target or biomarker.

Current Treatment for DCUN1D1-related Disorders

Currently, there are no known treatments that specifically target DCUN1D1. However, there are some drugs that are currently being developed to treat conditions that are associated with DCUN1D1. For example, some studies have suggested that inhibitors of DCUN1D1, such as colchicine, may be able to treat certain forms of cancer. Colchicine is a natural compound that has been used for centuries as a treatment for a variety of conditions, including cancer. In some studies, colchicine has been shown to inhibit the activity of DCUN1D1 and to lead to the death of cancer cells.

Another potential treatment for DCUN1D1-related disorders is the use of drugs that specifically target the UCP pathway. The UCP pathway is a complex network of proteins that is involved in the regulation of intracellular energy metabolism. Some studies have suggested that drugs that specifically target UCP proteins, including DCUN1D1, may be able to treat a wide range of conditions, including cancer, neurodegenerative diseases, and respiratory disorders.

The Potential for DCUN1D1 as a Drug Target

While currently there are no known treatments for DCUN1D1-related disorders, the potential for this protein as a drug target is being actively explored. DCUN1D1 has been shown to be involved in a wide range of cellular processes that are important for brain development and function. As such, it is possible that DCUN1D1 could be a useful target for drugs that are designed to modulate brain function or protect against brain damage.

One potential way to target DCUN1D1 is through the use of small molecules that can inhibit the activity of the protein. These small molecules could be designed to specifically target the active site of the DCUN1D1 protein, allowing them to interact with the protein and disrupt its function. Alternatively, these small molecules could be designed to interact with the protein's substrate, such as a specific amino acid residue, in a way that alters the protein's activity.

Another potential approach to targeting DCUN1D1 is through the use of antibodies that are designed to specifically recognize and bind to the protein. These antibodies could be used to either block the activity of the protein or to selectively target the protein in certain cells.

The Potential for DCUN1D1 as a Biomarker

In addition to its potential as a drug target, DCUN1D1 may also be a useful biomarker for a variety of diseases. The UCP pathway is involved in the regulation of a wide range of cellular processes, including stress response, DNA damage repair, and cell survival. As such, changes in the level of DCUN1D1 activity may be an indicator of the presence of certain diseases.

For example, DCUN1D1 levels have been shown to be elevated in the brains of individuals with certain forms of cancer, including neurofibromatosis and melanoma. Similarly, DCUN1D1 levels have been shown to be elevated in the hearts of individuals with certain forms of heart disease, such as hypertension and heart failure.

In addition to its potential as a biomarker, DCUN1D1 may also be

Protein Name: Defective In Cullin Neddylation 1 Domain Containing 1

Functions: Part of an E3 ubiquitin ligase complex for neddylation (PubMed:18826954). Promotes neddylation of cullin components of E3 cullin-RING ubiquitin ligase complexes (PubMed:26906416, PubMed:23201271, PubMed:19617556, PubMed:23401859). Acts by binding to cullin-RBX1 complexes in the cytoplasm and promoting their nuclear translocation, enhancing recruitment of E2-NEDD8 (UBE2M-NEDD8) thioester to the complex, and optimizing the orientation of proteins in the complex to allow efficient transfer of NEDD8 from the E2 to the cullin substrates. Involved in the release of inhibitory effets of CAND1 on cullin-RING ligase E3 complex assembly and activity (PubMed:25349211, PubMed:28581483). Acts also as an oncogene facilitating malignant transformation and carcinogenic progression (By similarity)

The "DCUN1D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCUN1D1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3